Solid Cancer
Research on solid cancer discussed by scientists at Kobe University
Published in Oncology Business Week, August 31st, 2008
"Sorafenib is a novel oral multikinase inhibitor that targets Raf serine/threonine and receptor tyrosine kinases, and inhibits tumor cell proliferation and angiogenesis. We have conducted a phase I study of sorafenib to determine the safety, tolerability, pharmacokinetics, and potential efficacy of this agent in 31 Japanese patients with advanced refractory solid tumors," investigators in Kobe, Japan report.
"Sorafenib (100-600 mg) was given as a single dose followed by a 7-day wash-out period, and then administrated twice daily (bid). The most frequent drug-related adverse events were rash/desquamation (61%), hand-foot skin reactions (39%), diarrhea (36%), and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- Abraxis BioScience
CNSI at UCLA to Host Forum on New Technologies for Brain, Spinal Trauma - Abraxis BioScience, Inc.
Abraxis BioScience Reports Financial Results for the Second Quarter of 2008 - AeroScout, Inc.
AeroScout's Visibility Solution Optimizes Workflow and Improves Patient Care for Oakwood Hospital & Medical Center - American Botanical Council
ABC Releases Monograph on Scientific Research of POM Wonderful Pomegranate Juice - American Botanical Council
ABC Releases Monograph on Scientific Research of POM Wonderful(R) Pomegranate Juice - Argos Therapeutics
Argos Therapeutics to Discuss Automated Manufacturing Process for its Arcelis Personalized Immunotherapy Platform - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
